Terminal
CFO – Kenneth Kovan
Auditors – DMCL
NOTE: To avoid any delays in the dissemination of your press release, Please ensure that you have provided the City/State of Origin, Date/Time, Contact Information (Name/Phone/Email) and Source of the press release along with an email id for us to include that in the press release: Company or Media contact as follows: Note that a name, email id, and a phone number are mandatory for media contact details according to our editorial guidelines
BioVaxys Technology Corp.
BVAXF
Biotechnology
Healthcare
biovaxys.com
646 452 7054
BioVaxys Technology Corp., a clinical-stage immunotherapeutic company, engages in developing antiviral and anticancer vaccine platforms. It develops BVX-0320, a SARS-CoV-2 vaccine; BVX-1021, a vaccine for the strain of coronavirus that causes SARS1; and BVX-0918, a haptenized tumor cell vaccine for ovarian cancer, as well as CoviDTH, a novel diagnostic platform to identify a T-cell immune response to the presence of SARS-CoV-2. The company is also developing Papilocare for human papilloma virus (HPV)-dependent cervical lesions. It has a bioproduction agreement with WuXi Biologics Limited to produce SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH; and research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320. BioVaxys Technology Corp. is based in Vancouver, Canada.
Portfolio Tracker
Supported Exchanges = LSE, TSX, NYSE, NASDAQ
Supported Currencies = USD, GBP
